Boehringer Ingelheim Pharmaceuticals brings a little German drugmaking know-how to the USA. The firm is the pharmaceuticals unit of Boehringer Ingelheim Corporation, which is the US headquarters of Germany's Boehringer Ingelheim. It sells a range of prescription and over-the-counter drugs in the US market, including respiratory treatments Spiriva and Atrovent; high blood pressure medication Micardis; enlarged prostate treatment Flomax; Parkinson's disease drug Mirapex; and HIV/AIDS products Aptivus and Viramune. It is also an R&D center for Boehringer Ingelheim, specializing in immunology, inflammatory conditions, and cardiovascular disease.

YM BioSciences USA Inc. company develops products for treating cancer and other related conditions. Its product candidates come out of Canadian parent company YM BioSciences Inc.' biotechnology portfolio. It is conducting clinical trials on nimotuzumab, a monoclonal antibody treatment targeting brain-cancer, for use in pediatric patients and for use in treating other solid tumor cancers in all patients. YM BioSciences also targets cancer-related pain. YM BioSciences USA changed its name from EXIMIAS Pharmaceutical a number of years ago when it was acquired by, and became a wholly owned subsidiary of, YM Biosciences Inc.

Abbott GmbH wants to cure what ails you. A subsidiary of Abbott Labs, the company has production facilities in four German cities. The Wiesbaden facility produces biopharmaceuticals used to treat rheumatoid arthritis and HIV/AIDS, as well as hospital and nutritional products. It also houses the company's diagnostics sales department. The Ludwigshafen complex (one of Abbott's largest pharmaceutical production sites outside the US) is home to Abbott Labs' European clinical trials, high-tech drug production, and R&D operations. Wetzlar houses Abbott Vascular Management while Rangendingen houses a vascular instrument manufacturing plant where balloon catheters, stents, and stent delivery systems are made.

Luitpold Pharmaceuticals earns its gold from the businesses of drugs and medical devices. Luitpold markets and manufactures injectable products used to treat an array of ailments including kidney disease. Luitpold also manufactures materials used in dental bone grafting and bone regeneration and treatments for equine and canine joint diseases. The company, which targets its products primarily to hospitals and clinics in US and Canadian markets, operates through four divisions: American Regent, Luitpold Animal Health, Osteohealth, and Contract Manufacturing. Originally a German company named after a Bavarian prince, Luitpold is a subsidiary of one of Japan's largest pharmaceutical companies, Daiichi Sankyo.

MethylGene's endeavors in the field of medicine may earn it a good look. The company is developing enzyme inhibitors to treat cancer and various infectious diseases. It develops product candidates for treatments for ailments such as solid tumors and hematological malignancies. MethylGene has also researched therapies to battle conditions including fungal infections and antibiotic resistance. The company forms licensing and collaboration agreements with other pharmaceutical firms to further its development programs.

Biovitrum company makes pharmaceuticals that treat hemophilia and autoimmune diseases like rheumatoid arthritis, scleroderma (hardening of the skin), and others. Its available products include arthritis drug Kineret and cancer side-effect drug Kepivance. Biovitrum company also has drugs for inflammatory diseases and absorption disorders in development in its pipeline. Biovitrum distributes its products to Europe, Australia, and the US through partnerships with pharmaceutical giants like Pfizer and Amgen.

Advanced Life Sciences Holdings, Inc. company was founded in 1999 and is headquartered in Woodridge, Illinois. Advanced Life Sciences Holdings, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of drugs in the areas of infectious disease, oncology and respiratory disease. The Company has assembled a pipeline of clinical and preclinical product candidates. In September 2008, the Company entered into a development and commercialization agreement with Wyeth for cethromycin in the Asia Pacific region excluding Japan. Advanced Life Sciences Holdings, Inc. has a worldwide license (excluding Japan) from Abbott Laboratories (Abbott) to develop and commercialize cethromycin, once-a-day antibiotic for the treatment of respiratory tract infections. On September 30, 2008, the Company submitted a new drug application for the use of cethromycin in community acquired pneumonia.

Qiagen N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands. Qiagen N.V. provides technologies and products for preanalytical sample preparation and linked molecular assay solutions worldwide. Its sample technologies are used to collect, stabilize, isolate, and purify deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins from blood, bone, and tissue samples; and assay technologies are used to make specific target biomolecules, such as the DNA of a specific virus for subsequent detection and analysis. The company offers sample and assay consumable products that are used in plasmid, DNA purification; RNA purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. It also provides PCR assays, which allow PCR-based detection of viral, bacterial and parasite, human, and animal pathogens, as well as pharmacogenomic genotyping; and various other products for research in the areas of epigenetics, gene expression, micro RNA, proteomics, RNAi, and applied testing and molecular diagnostics. In addition, the company offers automated systems that provide walk-away automation of sample and assay technologies in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks; QIAcube, which allows users in research in life sciences, applied testing, and molecular diagnostic to automate the processing of the company's consumable products; and instruments to OEM partners. Further, it provides custom services, such as whole genome amplification services, DNA sequencing, and non-cGMP DNA production on a contract basis; and sells and/or licenses technology. The company serves researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories.

Aspreva Pharmaceuticals believes that bad aim can be a good thing when treating diseases. This company conducts clinical trials to find new uses for approved drugs. As a result, partners team up with Aspreva to gain incremental revenue from the commercialization of the new version of the drug. Working in collaboration with Roche, Aspreva conducts clinical trials to investigate the use of Roche's CellCept (indicated for prevention of rejection in organ transplant patients) to treat autoimmune diseases including lupus nephritis and pemphigus vulgaris. Aspreva is a subsidiary of Swiss pharmaceutical firm Galenica Group.

Quarks may be the basic building blocks of matter, but it's a fundamental unit of biology -- genes -- that Quark Pharmaceuticals is interested in. The drug development company is using cutting-edge RNA interference (RNAi) technology to develop small-interfering RNA (siRNA) molecules, or drugs that inhibit targeted genes from producing proteins associated with certain diseases. Its lead product RTP801i-14, which it has licensed to Pfizer, aims to treat wet age-related macular degeneration (a cause of blindness in the elderly). Quark Pharmaceuticals is developing other candidates for ailments such as acute renal (kidney) failure, hearing loss, and dyslipidemia (a metabolic syndrome).

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.